The Relationship Between Vimentin Expression And Prognosis In Breast Carcinoma

Objective The clinical features and prognosis of breast carcinoma in patients with different molecular phenotypes,as well as the expression of Vimentin were analyzed.Correlation statistics was used to investigate whether Vimentin could be used as a prognostic marker for breast carcinoma.Methods Retrospective analysis of clinical and pathological data of 71 cases of female patients,who were 18-70 years old and initially diagnosed as breast carcinoma in Lanzhou General Hospital,without pregnant.And all specimen were collected from June 2008 to November 2011.Paraffin-embedding samples were uesd to make tissue microarray,by immunohistochemical staining,they were divided into four phenotypes according to Perou and Sorlie:(1)Luminal A phenotype: ER/PR(+),HER-2(-),Ki-67?14%;(2)Luminal B phenotype: ER/PR(+),HER-2(+)/ER/PR(+),HER-2(-),Ki-67>14%;(3)HER-2 over-expression phenotype: ER(-),PR(-),HER-2(+);(4)triple negative phenotype: ER(-),PR(-),HER-2(-).Among our cases,the numbers of Luminal A,Luminal B,HER-2 over-expression and triple negative phenotype were 21,21,6 and 23,respectively.We analyzed the clinical features and prognosis of breast carcinoma in patients with different molecular phenotypes,as well as expression of Vimentin by immunohistochemical staining,to study the correlation between them.Follow-up study was preceded to achieve data for survival status at the same time.Further to explore whether Vimentin could be a predictor of breast carcinoma.Results 1.The positive rate of Vimentin was respectively 24%(5/21)?38%(8/21)?50%(3/6)and 74%(17/23)in Luminal A?Luminal B?HER-2 over-expression and triple negative.The difference of Vimentin positive expression rate between triple negative phenotype and Luminal A / Luminal B phenotype was statistically significant(P?0.05);The difference of Vimentin positive rate between HER-2 over-expression phenotype and Luminal A or Luminal B phenotype was not statistically significant(P>0.05).Positive expression of Vimentin was related to clinical stage and lymph node metastsis of breast carcinoma in patients,(P?0.05),while that of age,tumor size and menstrual status was not statistically significant(P>0.05).2.In Vimentin-positive and negative patients,the number of PFS was 16(35.6%)and 29(64.4%)respectively and that of OS was 19(36.5%)and 33(63.5%)respectively(P?0.05).In triple negative phenotype patiens of Vimentin-positive and negative,the number of OS was 5(50.0%)and 5(50.0%)respectively(P?0.05).3.Multivariate analysis showed in breast carcinomas that ?-? clinical stage was a independent factor of poor prognosis for positive expression of Vimentin(P?0.05).4.Among the 71 cases studies,there were 21 cases of Luminal A phenotype(29.5%),21 cases of Luminal B phenotype(29.5),6 cases of HER-2 over-expression phenotype(8.6%)and 23 cases of triple negative phenotype(32.4%).HER-2 over-expression and triple negative phenotype had higher clinical stage than Luminal A / Luminal B phenotype(P?0.05).The difference was not statistically significant with age,tumor size,lymph node metastsis and menstrual status in four phenotypes(P>0.05).5.Patients with HER-2 over-expression phenotype and triple negative phenotype had a poor 5 years PFS than with Luminal A phenotype(P?0.05).Meanwhile patients with triple negative phenotype had a poor 5 years OS than with Luminal A phenotype(P?0.05).A comparison of curves for OS in four molecular phenotypes of breast carcinomas,the difference was statistically significant with Luminal A / Luminal B and triple negative(P?0.05).Conclusion 1.In breast carcinoma patients with Vimentin-posive had higher clinical stage and rate of lymph node metastasis as well as shorter five years of PFS and OS than Vimentin-negative one.2.In four molecular phenotypes,there was a higher expression of Vimentin in HER-2 over expression and triple negative phenotype than that in Luminal A / Luminal B.HER-2 over-expression and triple negative phenotype had higher clinical stage and shorter 5 years PFS and OS than Luminal A / Luminal B phenotype.?-? clinical stage was a independent factor of poor prognosis for breast carcinomas.3.Vimentin could be a predictor of breast carcinoma,as well as a prognostic indicator of triple negative phenotype.